Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Zanubrutinib and Lenalidomide as Maintenance Therapy in Patients With Diffuse Large B-cell Lymphoma

NCT06503263 is registered in ClinicalTrials.gov with Navy General Hospital, Beijing as lead sponsor.

NCT NCT06503263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06503263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Zanubrutinib and Lenalidomide as Maintenance Therapy in Patients With Diffuse Large B-cell Lymphoma
Lead sponsor
Navy General Hospital, Beijing
Phase
Phase 2
Overall status
Recruiting
Start date
August 30, 2024
Completion date
December 30, 2030
Enrollment
240 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma